These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 35433835)

  • 1. Using Structure-guided Fragment-Based Drug Discovery to Target
    Arif SM; Floto RA; Blundell TL
    Front Mol Biosci; 2022; 9():857000. PubMed ID: 35433835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers Retain Activity against Multidrug-Resistant Pseudomonas aeruginosa
    Moustafa DA; Wu AW; Zamora D; Daly SM; Sturge CR; Pybus C; Geller BL; Goldberg JB; Greenberg DE
    mBio; 2021 Jan; 12(1):. PubMed ID: 33436433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Building Blocks of Antimicrobial Resistance in
    Langendonk RF; Neill DR; Fothergill JL
    Front Cell Infect Microbiol; 2021; 11():665759. PubMed ID: 33937104
    [No Abstract]   [Full Text] [Related]  

  • 4. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and Phenotypic Diversity of Staphylococcus aureus Isolates from Cystic Fibrosis Patient Lung Infections and Their Interactions with Pseudomonas aeruginosa.
    Bernardy EE; Petit RA; Raghuram V; Alexander AM; Read TD; Goldberg JB
    mBio; 2020 Jun; 11(3):. PubMed ID: 32576671
    [No Abstract]   [Full Text] [Related]  

  • 6. Phenotypic and Genotypic Adaptations in Pseudomonas aeruginosa Biofilms following Long-Term Exposure to an Alginate Oligomer Therapy.
    Oakley JL; Weiser R; Powell LC; Forton J; Mahenthiralingam E; Rye PD; Hill KE; Thomas DW; Pritchard MF
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33472983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT.
    Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR
    Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging strategies to target virulence in
    Hibbert TM; Whiteley M; Renshaw SA; Neill DR; Fothergill JL
    Crit Rev Microbiol; 2023 Nov; ():1-16. PubMed ID: 37999716
    [No Abstract]   [Full Text] [Related]  

  • 9. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung.
    Hogardt M; Heesemann J
    Curr Top Microbiol Immunol; 2013; 358():91-118. PubMed ID: 22311171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneous Antimicrobial Susceptibility Characteristics in
    Qin X; Zhou C; Zerr DM; Adler A; Addetia A; Yuan S; Greninger AL
    mSphere; 2018; 3(2):. PubMed ID: 29564400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
    Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD005405. PubMed ID: 27412131
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Orazi G; O'Toole GA
    mBio; 2017 Jul; 8(4):. PubMed ID: 28720732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Small RNA ErsA Plays a Role in the Regulatory Network of Pseudomonas aeruginosa Pathogenicity in Airway Infections.
    Ferrara S; Rossi A; Ranucci S; De Fino I; Bragonzi A; Cigana C; Bertoni G
    mSphere; 2020 Oct; 5(5):. PubMed ID: 33055260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2013 Oct; (10):CD005405. PubMed ID: 24170644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral anti-pseudomonal antibiotics for cystic fibrosis.
    Remmington T; Jahnke N; Harkensee C
    Cochrane Database Syst Rev; 2007 Jul; (3):CD005405. PubMed ID: 17636796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermutator Pseudomonas aeruginosa Exploits Multiple Genetic Pathways To Develop Multidrug Resistance during Long-Term Infections in the Airways of Cystic Fibrosis Patients.
    Colque CA; Albarracín Orio AG; Feliziani S; Marvig RL; Tobares AR; Johansen HK; Molin S; Smania AM
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071060
    [No Abstract]   [Full Text] [Related]  

  • 18. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
    Greally P; Whitaker P; Peckham D
    Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-
    Elmassry MM; Colmer-Hamood JA; Kopel J; San Francisco MJ; Hamood AN
    Microorganisms; 2023 Mar; 11(4):. PubMed ID: 37110338
    [No Abstract]   [Full Text] [Related]  

  • 20. Heterogenous Susceptibility to R-Pyocins in Populations of Pseudomonas aeruginosa Sourced from Cystic Fibrosis Lungs.
    Mei M; Thomas J; Diggle SP
    mBio; 2021 May; 12(3):. PubMed ID: 33947755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.